A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
Public ClinicalTrials.gov record NCT02341508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab Administered Intravenously to Healthy Volunteers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to evaluate the safety and tolerability of Lpathomab in healthy volunteers. Additional endpoints include characterization of the pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity profiles of a single IV dose of Lpathomab in healthy volunteers.
Study identification
- NCT ID
- NCT02341508
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- 0.5 mg/kg Lpathomab Biological
- 1.0 mg/kg Lpathomab Biological
- 3.0 mg/kg Lpathomab Biological
- 10 mg/kg Lpathomab Biological
- 20 mg/kg Lpathomab Biological
- Saline solution for intravenous infusion Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2015
- Primary completion
- Feb 29, 2016
- Completion
- Feb 29, 2016
- Last update posted
- May 5, 2016
2015 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| PRA Health Sciences | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Healthy Subjects trials
Other public records listing Healthy Subjects. Sorted by last update posted; newest first. Not a recommendation.
- NCT07209423: Shoulder Strength in Baseball Players Recruiting
- NCT02417714: Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR) Recruiting
- NCT07395609: High Frequency Stimulation to Improve Cognition, Mobility, and Affect in Individuals With Subjective Cognitive Decline Not yet recruiting
- NCT07081217: Radiocaine Safety Study Recruiting
- NCT01568697: Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis) Recruiting
- NCT06014515: Single-tracer Multiparametric PET Imaging Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02341508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2016 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02341508 live on ClinicalTrials.gov.